|
 BOSTON (AP) - It was barely two hours after a panel recommended to the Food and Drug Administration that it allow the drug Tysabri back on the market when Dr. Joseph Berger got an e-mail inviting him to a special class.
Would Berger, a neurologist at the University of Kentucky's Multiple Sclerosis Clinic, be interested in earning credits toward updating his medical license by learning more about Tysabri, a treatment for multiple sclerosis?
"The marketing people at Biogen Idec are brilliant," Berger said, "I think every one of these companies has these various shadow organizations, and that's how they get their message out without being necessarily linked to it."
|